Milrinone Disease Interactions
There are 6 disease interactions with milrinone.
Milrinone (applies to milrinone) arrhythmias
Major Potential Hazard, Moderate plausibility.
The use of milrinone both intravenously and orally has been associated with increased frequency of ventricular arrhythmias, including nonsustained ventricular tachycardia. Long-term oral use has been associated with an increased risk of sudden death. Hence, patients receiving milrinone should be observed closely with the use of continuous electrocardiographic monitoring to allow the prompt detection and management of ventricular arrhythmias.
Milrinone (applies to milrinone) heart valve disease
Major Potential Hazard, Moderate plausibility. Applicable conditions: Valvular Heart Disease
Milrinone should not be used in patients with severe obstructive aortic or pulmonic valvular disease in lieu of surgical relief of the obstruction. Like other inotropic agents, it may aggravate outflow tract obstruction in hypertrophic subaortic stenosis.
Milrinone (applies to milrinone) myocardial infarction
Major Potential Hazard, Moderate plausibility.
No clinical studies have been conducted with milrinone in patients in the acute phase of post myocardial infarction. Until further clinical experience with this class of drugs is gained, milrinone is not recommended in these patients.
Amrinone (applies to milrinone) liver disease
Moderate Potential Hazard, Moderate plausibility.
The use of inamrinone (former amrinone) has been associated with hepatotoxicity, manifested as marked alterations in liver function tests and clinical symptoms suggestive of idiosyncratic hypersensitivity. This especially after long-term use. Therapy with inamrinone should be administered cautiously if at all in patients with liver disease and discontinuation of the drug may be required if symptoms worsen. Monitoring of liver functions tests prior to and during therapy is recommended.
Amrinone/milrinone (applies to milrinone) hypotension
Moderate Potential Hazard, High plausibility.
The use of amrinone or milrinone is associated with a fall in blood pressure. Some patients have required correction by intravenous infusion of plasma. Therapy with amrinone or milrinone should be administered cautiously in hypotensive patients. Monitoring fluid and electrolyte status, renal function, blood pressure, and heart rate is recommended.
Amrinone/milrinone (applies to milrinone) thrombocytopenia
Moderate Potential Hazard, Low plausibility.
The use of amrinone, and infrequently, milrinone, can cause thrombocytopenia. This appears to be dose-dependent and usually occurs during prolonged therapy. Therapy with amrinone and milrinone should be administered cautiously in patients with thrombocytopenia. The dosage may need to be reduced or the drug discontinued if platelet count falls below 150,000/mm3 or if symptoms develop. Platelet counts prior and during therapy are recommended.
Milrinone drug interactions
There are 24 drug interactions with milrinone.
Report options
More about milrinone
- milrinone consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Side effects
- Dosage information
- During pregnancy
- Drug class: inotropic agents
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.